GlassScriptPhysician profile
Gary Leuropa
NPI 1891780706
$6,708.74
in general payments reported to CMS, 2019-2025
25 companies · $1,171 in 2025
The $1,171 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $741 · 2020: $386 · 2021: $1,245 · 2022: $898 · 2023: $1,118 · 2024: $1,151 · 2025: $1,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,439.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,431.82 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $1,025.94 | 2020-2021 | |
| Lundbeck LLC | $973.41 | 2023-2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $684.22 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Amgen INC. | $494.71 | 2019-2024 | Aimovig |
| Biohaven Pharmaceutical Holding Company LTD. | $427.68 | 2022 | |
| Lilly USA, LLC | $387.08 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Pfizer INC. | $382.41 | 2023-2025 | |
| Allergan, INC. | $286.01 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $107.45 | 2019-2021 | |
| Eisai INC. | $79.59 | 2019 | |
| Novartis Pharmaceuticals Corporation | $54.88 | 2020-2021 | |
| Kyowa Kirin, INC. | $52.56 | 2019-2020 | |
| Upsher-Smith Laboratories LLC | $46.72 | 2020-2021 | |
| Assertio Therapeutics, INC. | $39.66 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $39.23 | 2020 | |
| Avanir Pharmaceuticals, INC. | $36.06 | 2019 | |
| Axsome Therapeutics, INC. | $27.84 | 2025 | Symbravo |
| Mallinckrodt Enterprises LLC | $24.54 | 2019 | |
| Supernus Pharmaceuticals, INC. | $19.56 | 2022 | |
| Sunovion Pharmaceuticals INC. | $19.49 | 2019 | |
| Tanabe Pharma America, INC. | $18.77 | 2019 | |
| Promius Pharma LLC | $16.99 | 2019 | |
| Impel Pharmaceuticals INC. | $16.71 | 2023 | Trudhesa |
| Genzyme Corporation | $15.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Leuropa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.